1 omplications in the family members with this dysfibrinogenemia.

2 ologies, diabetes, thrombolytic therapy, and dysfibrinogenemia.

3 itative alterations; the latter are known as dysfibrinogenemias.

4 RP and also in platelets from a patient with dysfibrinogenemia and a fibrinogen polymerization defect

5 with the observation that subjects with this dysfibrinogenemia are asymptomatic.

6 ting that it is a relatively common cause of dysfibrinogenemia-associated thrombosis.

7 center study of 101 patients with congenital dysfibrinogenemia (CD) to characterize the incidence of

8 scular coagulation (DIC), hyperfibrinolysis, dysfibrinogenemia, hemolysis, and a decrease in number o

9                                This acquired dysfibrinogenemia is characterized by fibrin clots that

10                                           In dysfibrinogenemias, structural defects cause alterations

11 h corresponding heterozygous gene mutations (dysfibrinogenemias) were observed in 5 of 33 CTEPH patie

12 erization of fibrinogen Dusart, a congenital dysfibrinogenemia with the amino acid substitution A alp